You are here

580b57fcd9996e24bc43c53e   LinkedIn Logo 500x500   Facebook logo square   Iguana Trans cropped

event icon
Date
27.10.22 - 28.10.22
Complutense University of Madrid, Spain

The British Pharmacological Society present a focused meeting on recent advances in cannabinoid therapeutics for Dravet syndrome


Cannabinoids are currently being investigated for their potential as antiepileptic agents in Dravet syndrome and other infantile epileptic encephalopathies, which derived in the recent approval of Epidiolex (cannabidiol) for the treatment of seizures in these syndromes. Additional studies conducted in preclinical models have also demonstrated the potential of cannabidiol, but also other cannabinoids, to attenuate the numerous long-term comorbidities occurring in patients, then possibly serving as potential disease modifiers. Such recent biomedical advances will be updated in this meeting, which will contribute to review:

  • the current status of cannabinoid therapeutics
  • the potential of cannabinoids as antiepileptic agents
  • the current overview on infantile refractory epileptic encephalopathies
  • the tools available for preclinical research in these disorders
  • the development of cannabidiol in the pediatric field
  • the interactions of cannabidiol with other antiepileptic agents in Dravet syndrome
  • the potential of cannabinoids as disease modifiers in these disorders

Learning outcomes

The meeting is intended to serve:
  • to update the current scientific knowledge on this topic
  • to facilitate a further development of cannabinoid therapeutics for these disorders
  • to strengthen the research and the collaboration between preclinical and clinical researchers, and both with companies
  • to respond to important demands from patients and families

Further details

Visit the BPS website for additional information.